FX06: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 49 patientsc19early.org

FX06 for COVID-19

Serious outcome risk
FX06
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−10%
Mortality (1)−10%
RCTs (1)−10%
Late (1)−10%
00.511.5+
← FX06
reduces riskIncreased
risk →
c19early.org
October 2026

FX06 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Guérin (DB RCT)−10%1.10 · 0.47–2.56death8/257/24Ventilated patients
Late treatment−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.84
All studies−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8400.511.52+
Rotate screen for more detailsIncrease width for more details
← FX06
reduces riskFX06
increases risk →
c19early.org
October 2026

FX06 COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Guérin (DB RCT)−10%1.10 · 0.47–2.568/257/24Ventilated patients
Late treatment−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.84
All studies−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8400.511.52+
Rotate screen for more detailsIncrease width for more details
← FX06
reduces riskFX06
increases risk →
c19early.org
October 2026

FX06 COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Guérin (DB RCT)−10%1.10 · 0.47–2.56death8/257/24Ventilated patients
Late treatment−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.84
All studies−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8400.511.52+
Rotate screen for more detailsIncrease width for more details
← FX06
reduces riskFX06
increases risk →
c19early.org
October 2026

FX06 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Guérin (DB RCT)−10%1.10 · 0.47–2.56death8/257/24Ventilated patients
Late treatment−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.84
All studies−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8400.511.52+
Rotate screen for more detailsIncrease width for more details
← FX06
reduces riskFX06
increases risk →
c19early.org
October 2026

FX06 COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Guérin (DB RCT)−10%1.10 · 0.47–2.568/257/24Ventilated patients
Late treatment−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.84
All studies−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8400.511.52+
Rotate screen for more detailsIncrease width for more details
← FX06
reduces riskFX06
increases risk →
c19early.org
October 2026

FX06 COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Guérin (DB RCT)−10%1.10 · 0.47–2.56death8/257/24Ventilated patients
Late treatment−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.84
All studies−10%1.10 · 0.47–2.568/257/2410% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8400.511.52+
Rotate screen for more detailsIncrease width for more details
← FX06
reduces riskFX06
increases risk →